VIDEO: Pembrolizumab ‘should be standard of care’ for stage II or III triple-negative breast cancer
Click Here to Manage Email Alerts
Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, talked about survival data from KEYNOTE-522 that have been awaited with “a lot of anticipation.”
KEYNOTE-522 has previously shown the benefit of adding pembrolizumab (Keytruda, Merck) to chemotherapy in some patients with triple-negative breast cancer, but Tolaney told Healio that the data presented at ESMO showed this improved OS as well.
“I think this is really critical for our patients because it does solidify that pembrolizumab really should be standard of care for all patients who have stage II or III triple-negative breast cancer,” Tolaney said in a video interview. “I think it also really highlights the critical nature of administering preoperative therapy to patients who have stage II and III triple-negative disease because it is translating into a survival difference for these patients.”
Reference:
Collapse
Read more about
Click Here to Manage Email Alerts